drug
polatuzumab vedotin
Marketedupdated 6mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
DLBCL
all catalysts(4)
approval · 4
Jun 10, 2019
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Sep 18, 2020
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Apr 19, 2023
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Mar 18, 2026
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Trials studying polatuzumab vedotin
- phase2Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
- phase2Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
- phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- phase1A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
- phase2TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- phase1Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
- phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
News(7)
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 27d ago
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreNew data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…biospace · 1mo ago
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.biopharma_dive · 1mo ago
- AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…biospace · 1mo ago
- AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to PolivyAbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market showdown with Roche’s antibody-dru…endpoints · 1mo ago
- Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioThrough its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.biospace · 2mo ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 3mo ago
Data sources
last refreshed 8h ago
Found something off?
comments(0)
5-min edit window · permanent after that